NexImmune’s lead program is an adoptive cellular therapy to treat Acute Myeloid Leukemia (AML) and Myeloid Dysplastic Syndrome (MDS) patients that have relapsed disease following Hematopoietic Stem Cell Transplant (HSCT).
PBMC’s from a donor are used to enrich and expand AML-specific CD8+ T cells using NexImmune’s proprietary AIM System. The AML cell therapy product is expected to enter clinical trials in 2018.
ABOUT AML: There is an increasing unmet need in AML due to growing incidence, lack of new treatment options and an aging population. It is estimated that >70% of these patients have a poor outcome. Of the estimated 21,300 patients in the US, approximately 45% of these patients receive a hematopoetic stem cell transplant (HSCT). While transplant offers benefit, more than half of these patients will have a relapse of their leukemia. For high risk patients, the one year mortality rate is 90%. There are no new treatment options available for patients with relapsed AML following HSCT treatment.Learn More About AIM ACT
AIM 101 is a direct injectable aAPC cocktail that represents a precisely manufactured pharmaceutical product.
AIM 101 is an ideal application for rapid loading and delivery of known tumor associated antigens of choice or neoantigens corresponding to individual patients.Learn More About AIM 101